New cancer drug SHR-4298 enters early human testing

NCT ID NCT07229612

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study is testing an experimental drug called SHR-4298 in 200 people with advanced solid tumors that cannot be removed by surgery or cured by standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow cancer growth. The trial is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-4298 injection
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early phase 1/2 trial with only 200 participants, so it is too soon to know if the drug works or is safe. Side effects are unknown and the drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMORS

Contacts and locations

Locations

The First Affiliated Hospital of Guangzhou Medical University
RECRUITING

Guangzhou, Guangdong, 510032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.